Compare VYGR & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VYGR | CUE |
|---|---|---|
| Founded | 2013 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 193.5M | 177.0M |
| IPO Year | 2015 | 2017 |
| Metric | VYGR | CUE |
|---|---|---|
| Price | $1.62 | $4.59 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 3 |
| Target Price | $14.22 | ★ $68.67 |
| AVG Volume (30 Days) | ★ 945.7K | 552.6K |
| Earning Date | 11-05-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 61.11 |
| EPS | ★ N/A | N/A |
| Revenue | $10,135,000.00 | ★ $27,466,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $172.11 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 195.75 |
| 52 Week Low | $1.48 | $0.17 |
| 52 Week High | $5.19 | $45.50 |
| Indicator | VYGR | CUE |
|---|---|---|
| Relative Strength Index (RSI) | 36.85 | 24.71 |
| Support Level | N/A | $0.22 |
| Resistance Level | $2.04 | $33.95 |
| Average True Range (ATR) | 0.15 | 2.75 |
| MACD | 0.01 | -1.47 |
| Stochastic Oscillator | 16.22 | 8.18 |
Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.
Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.